Ildong makes initial lead in the SGLT2·DPP4 combo market
By Kim, Jin-Gu | translator Kim, Jung-Ju
23.06.14 06:18:23
가나다라
0
AstraZeneca’s ‘Qtern’ prescription reach KRW 190 million in May, exceeding LG Chem’s ‘Zemidapa’ KRW 70 million
‘Sugadapa’ to enter the market in June...large amount of generics are set to enter the market after Januvia’s patent expiry in September
▲Pic of Qtern, Zemidapa, Esgliteo, and Sugadapa (clockwise from the upper left corner)
Full-fledged competition has begun in the ‘SGLT-2 inhibitor+DPP-4 inhibitor’ two-drug combination therapy market for the treatment of diabetes. In the first month after 5 products were launched, outpatient prescriptions reached KRW 300 million, and AstraZeneca and Ildong Pharmaceutical's Qtern led the market bringing in prescriptions of KRW 200 million.
This market is expected to expand further after the term expires for Januvia (sitagliptin) in September. Fierce competition is expected after the 86 generic companies release their two-drug combination of dapagliflozin + sitagliptin at the same time after September.
According to the market research institution UBIST, SGLT-2i+DPP
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)